Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models
Emmy D.G. Fleuren(Radboud University Medical Center), Winette T.A. van der Graaf(Radboud University Medical Center)
Cited by 21
Related Papers
The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
|Oncotarget|2014|47
Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507
|Clinical Cancer Research|2011|42
Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
|Cancer Research|2017|35
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo
|Journal of Cancer Research and Clinical Oncology|2020|27